Clarius Group LLC raised its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Get Rating) by 115.6% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 60,615 shares of the company’s stock after purchasing an additional 32,504 shares during the quarter. Clarius Group […]
Beam Therapeutics Inc. (NASDAQ:BEAM – Get Rating) has been given a consensus recommendation of “Moderate Buy” by the twelve research firms that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12-month price […]
Nikko Asset Management Americas Inc. boosted its stake in Beam Therapeutics Inc. (NASDAQ:BEAM – Get Rating) by 31.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 673,690 shares of the company’s stock after acquiring an additional 162,759 shares during the period. […]
Beam Therapeutics (NASDAQ:BEAM – Get Rating) had its price target reduced by Royal Bank of Canada from $50.00 to $42.00 in a research note issued to investors on Thursday morning, The Fly reports. A number of other analysts have also commented on the company. Sanford C. Bernstein initiated coverage on Beam Therapeutics in a report […]
Beam Therapeutics (NASDAQ:BEAM – Get Rating) had its target price decreased by Barclays from $45.00 to $41.00 in a report released on Thursday morning, The Fly reports. Several other research analysts have also commented on the company. William Blair restated an outperform rating on shares of Beam Therapeutics in a research report on Wednesday, March […]